Apriem Advisors’s West Pharmaceutical WST Stock Holding History

Apriem Advisors’s Portfolio WST Stock Details WST Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-44	Closed	-$4K	–	554
2017 Q1	$4K	Hold	44	–	–	﹤0.01%	531
2016 Q4	$4K	Hold	44	–	–	﹤0.01%	550
2016 Q3	$3K	Buy	+44	New	+$3.49K	﹤0.01%	523

Other funds holding WST

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return

Select Equity Group New York $20.2B AUM 17.52% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

BAMCO Inc New York $66.6B AUM 7.35% 1-Year Est. Return

EAM

Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return

Apriem Advisors's WST Position: Q2 2017 in Review

Apriem Advisors sold out of West Pharmaceutical (WST) in Q2 2017, closing a stake of 44 shares — an estimated $4K sold.

Apriem Advisors first reported a position in WST in Q3 2016 and held it in 3 quarters. The position peaked at $4K in Q1 2017. 310 funds tracked by Wall St. Rank hold WST as of Q2 2017.

Apriem Advisors reported no remaining West Pharmaceutical position as of Q2 2017 after selling out during the quarter.
Apriem Advisors sold 44 West Pharmaceutical shares in Q2 2017, an estimated $4K.
Apriem Advisors first reported a position in West Pharmaceutical in Q3 2016 and held it in 3 quarters.
Apriem Advisors's West Pharmaceutical position peaked at $4K in Q1 2017.
310 funds tracked by Wall St. Rank held West Pharmaceutical as of Q2 2017.

Based on Apriem Advisors's 13F filing for Q2 2017, filed 4 Aug 2017.